Dr. Peter Riedell
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 158
Licensed in Illinois since 2016, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036140692 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 158
- Services billed
- 922
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 259 | 90 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 189 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Chicago, IL | 103 |
| Brukinsa (zanubrutinib) | 52 |
| Venclexta (venetoclax) | 21 |
| Calquence (acalabrutinib maleate) | 20 |
| Prednisone Other prescribers in Chicago, IL | 16 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Chicago, IL | 16 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 14 |
| Allopurinol Other prescribers in Chicago, IL | 14 |
| Gabapentin Other prescribers in Chicago, IL | 14 |
| Duloxetine Hcl Other prescribers in Chicago, IL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 45 payments worth $37,844 in total to this clinician.
| AbbVie Inc. | $11,383 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $10,028 |
| Pfizer Inc. | $7,460 |
| Gilead Sciences, Inc. | $4,446 |
| Genentech USA, Inc. | $3,961 |
| Adc Therapeutics America, Inc. | $253 |
| Beone Medicines USA, Inc. | $186 |
| Genmab U.S., Inc. | $91.94 |
| Consulting Fee | $33,035 |
|---|---|
| Travel and Lodging | $2,516 |
| Food and Beverage | $1,358 |
| Compensation for services other than consulting (speaking, faculty) | $935 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 18, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,100 |
| E.r. Squibb & Sons, L.l.c. Jan 22, 2025 | Consulting Fee | $4,775 |
| Gilead Sciences, Inc. Jul 14, 2025 | Consulting FeeCompany’s description;4144497;GTF;11039083 | $4,330 |
| AbbVie Inc. Apr 16, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| E.r. Squibb & Sons, L.l.c. Jul 7, 2025 | Consulting Fee | $2,865 |
| Genentech USA, Inc. Mar 24, 2025 | Consulting Fee Lunsumio; Polivy · BioOncology | $2,460 |
| E.r. Squibb & Sons, L.l.c. Mar 27, 2025 | Consulting Fee | $2,388 |
| AbbVie Inc. Apr 16, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,813 |
| AbbVie Inc. Jan 21, 2025 | Consulting Fee | $1,450 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,088 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee | $760 |
| Pfizer Inc. Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $360 |
| AbbVie Inc. Jul 16, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $725 |
| Gilead Sciences, Inc. Jul 14, 2025 | Consulting FeeCompany’s description;4144497;GTF;11039083 | $4,330 |
| AbbVie Inc. Jul 10, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $363 |
| E.r. Squibb & Sons, L.l.c. Jul 7, 2025 | Consulting Fee | $2,865 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,088 |
| AbbVie Inc. Apr 16, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,900 |
| AbbVie Inc. Apr 16, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $1,813 |
| AbbVie Inc. Apr 16, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to CHICAGO, IL · in-kind | $95.43 |
| Genentech USA, Inc. Apr 10, 2025 | Consulting Fee | $570 |
| E.r. Squibb & Sons, L.l.c. Mar 27, 2025 | Consulting Fee | $2,388 |
| Pfizer Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $215 |
| Genentech USA, Inc. Mar 24, 2025 | Consulting Fee Lunsumio; Polivy · BioOncology | $2,460 |
| Pfizer Inc. Mar 18, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,100 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $578 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $268 |
| AbbVie Inc. Mar 15, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $37.33 |
| Pfizer Inc. Mar 14, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to San Diego, CA · in-kind | $528 |
| Pfizer Inc. Mar 14, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to San Diego, CA · in-kind | $504 |
| Pfizer Inc. Mar 14, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to San Diego, CA · in-kind | $393 |
| AbbVie Inc. Mar 14, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DALLAS, TX · in-kind | $112 |
| AbbVie Inc. Feb 13, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $363 |
| E.r. Squibb & Sons, L.l.c. Jan 22, 2025 | Consulting Fee | $4,775 |
| AbbVie Inc. Jan 21, 2025 | Consulting Fee | $1,450 |
| AbbVie Inc. Jan 10, 2025 | Consulting Fee | $1,088 |
| Pfizer Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $360 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $113,117 in research payments for these studies, mostly to the institutions running them.
- Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL
Novartis Pharmaceuticals Corporation - Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL
Hoffmann-la Roche Limited - A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2)
Kite Pharma, Inc. - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma
Novartis Pharmaceuticals Corporation - 2L ASCT eligible study in DLBCL glofit R ICE
Genentech, Inc. - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796 - A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7)
Kite Pharma, Inc. - A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA 3)
Kite Pharma, Inc. - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.